8 things you need to know about eCTDs in China
Although eCTDs are a huge step forward for standardization in the Asia Pacific, there are several important things you need to know before you submit your dossier electronically.
Read More
Although eCTDs are a huge step forward for standardization in the Asia Pacific, there are several important things you need to know before you submit your dossier electronically.
Read More
Parexel spoke with Doug Olson, Cancer survivor and CAR T-cell patient, about how healthcare providers and trial sponsors can better communicate with patients about CGTs.
Read More
Read More
Read More
Read More
Read five ways biotech companies can enhance their value story with advanced analytics.
Read More
Patient and site-centricity go hand-in-hand.
Read More
Read More
Read More
Read More
In this article, Parexel experts outline five approaches that foreign companies with limited resources should use to gain a foothold in the Chinese market.
Read More
Article from December 2021 edition of Applied Clinical Trials. Parexel regulatory experts offer top tips for working with regulators on a global scale.
Read More
Articulating a coherent product value story from the start of development can help companies attract investors.
Read More
Read More
Learn how one client gained several efficiencies in their complex Marketing Authorization Transfer project.
Read More
Learn how our integrated support and round-the-clock publishing saved valuable in-house resources for one client.
Read More
Although eCTDs are a huge step forward for standardization in the Asia Pacific, there are several important things you need to know before you submit your dossier electronically.
Read More
Submitting electronic dossiers is not the same in every country, in some cases their are several commonalities but also several differences.
Read More
In a two-part series, this second paper discusses driving RBQM adoption and what an effective RBQM change management program looks like.
Read More
Slides presented during virtual roundtable, entitled "Making expedited regulatory pathways work for global drug development programs"
Read More
Loading More...